Oncotarget

Research Papers:

Gene delivery and gene expression in vertebrate using baculovirus Bombyx mori nucleopolyhedrovirus vector

Xingjian Liu, Yinü Li, Xiaoyuan Hu, Yongzhu Yi and Zhifang Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:106017-106025. https://doi.org/10.18632/oncotarget.22522

Metrics: PDF 498 views  |   HTML 994 views  |   ?  


Abstract

Xingjian Liu1,*, Yinü Li1,*, Xiaoyuan Hu1, Yongzhu Yi2 and Zhifang Zhang1

1Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing, China

2The Sericultural Research Institute, Chinese Academy of Agricultural Sciences, Zhenjiang, China

*These authors have contributed equally to this work

Correspondence to:

Zhifang Zhang, email: zhifangzhang@yahoo.com

Keywords: Bombyx mori nucleopolyhedrovirus; complement resistance; gene delivery

Received: July 06, 2017     Accepted: October 28, 2017     Published: November 20, 2017

ABSTRACT

The baculovirus Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) has been investigated as a possible tool for gene therapy, but its inhibition by complement proteins in human serum limits its applicability. Here, we used the baculovirus Bombyx mori nucleopolyhedrovirus (BmNPV) to construct a gene delivery vector in which a reporter gene is driven by a cytomegalovirus IE promoter. Enhanced green fluorescent protein (EGFP) and luciferase reporter genes were used to test the efficiency of gene delivery. In vitro complement inactivation data showed that the recombinant BmNPV vector was more stable in human serum than the recombinant AcMNPV vector. The recombinant BmNPV vector successfully delivered the reporter genes into different tissues and organs in mice and chicks. These results demonstrate that the BmNPV vector is more stability against complement inactivation in human serum than the AcMNPV vector, and indicate that it may be useful as an effective gene delivery vector for gene therapy in vertebrates.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22522